Every round on record, with the sources behind each and the investors on them.
A privately held clinical-stage company developing CAR-T therapies
avencell.comLinkedIn500 Forge Road, Watertown, MA 02472, USABiotechFounded 202165 employees as of July 31, 2026
4 sources · checked 10 times, last 11h ago
Expected; not announced.
The announcement combines the Series C equity commitment with a separate royalty financing; the larger headline figure includes both, and the release says Series C details will be announced separately.
Publication audit: expected, not announced: "Ligand has also committed up to $6 million in concomitant Series C financing, details of which will be announced separately." (https://investor.ligand.com/news-and-events/press-releases/news-details/2026/Ligand-and-AvenCell-Therapeutics-Enter-Financing-Agreement-to-Advance-Pipeline-of-Next-Generation-CAR-T-Therapies-for-Up-to-47-Million/default.aspx)
1 source
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C Expected | $6M $47M to date | 2026-09-24 | not stated | No recent discussion |
4 sources · checked 10 times, last 11h ago Expected; not announced. [ VERIFIED ] read against 4 sources The announcement combines the Series C equity commitment with a separate royalty financing; the larger headline figure includes both, and the release says Series C details will be announced separately. Publication audit: expected, not announced: "Ligand has also committed up to $6 million in concomitant Series C financing, details of which will be announced separately." (https://investor.ligand.com/news-and-events/press-releases/news-details/2026/Ligand-and-AvenCell-Therapeutics-Enter-Financing-Agreement-to-Advance-Pipeline-of-Next-Generation-CAR-T-Therapies-for-Up-to-47-Million/default.aspx) | ||||
AvenCell develops switchable, autologous and allogeneic CAR-T immunotherapies for people with hard-to-treat cancers and autoimmune diseases.
Checked against 8 sources on Sep 28
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $112M | 2024-10-22 | Novo Holdings | No recent discussion |
1 source [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
Also named as backers in company research: Japan Agency for Medical Research and Development (AMED), SAB Sächsische Aufbaubank-Förderbank, European Union/ European Social Fund, Federal Ministry of Education and Research